← Russell 3000 cross-section

BDSX BIODESIX INC

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$316m
Revenue TTM
$103m
Net income TTM
$-28m
Free cash flow
$-20m
Composite score
34.3
Sector rank
#2626

Valuation

P / E
EV / EBITDA
EV / sales
3.3
FCF yield
-6.40%
Earnings yield vs 10-yr
-13.52pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-27.0%
EBITDA margin
ROE
-303.6%
ROIC
-70.7%
Revenue growth
34.5%

Insider activity, last 90 days

Net open-market
$1.03m
Buyers
1
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

“Risk Factors” for more information. Second Quarter 2026 Financial and Operational Highlights The following were significant developments affecting our business, capital structure and liquidity during the three months ended June 30, 2026 as compared to the same period in 2025 unless otherwise noted: • Diagnostic Testing revenue was $25.4 million in the second quarter, representing 42% growth, driven by a 38% increase in test volumes to 20,900 and higher average revenue per test year-over-year. …BIODESIX INC, 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →